Skip to main content

CTF-Funded Research Published in “Nature”

By January 31, 2024February 1st, 2024Featured, Featured EU, Science & Research

Important new study reveals that functional interactions between NF tumor suppressors drive Schwann cell tumor changes and treatment challenges

Findings also indicate that variants in both the NF1 and NF2 genes play a role in shaping the development and behavior of Schwann cell tumors, offering valuable knowledge for patients affected by neurofibromatosis type 1 (NF1) or NF2-related schwannomatosis (NF2-SWN).

In the quest to determine why Schwann cell tumors can become more aggressive and resistant to treatment, this significant study (funded by a CTF Young Investigator Award and others) dove deep into the understanding of Schwann cell tumors, which are often found in individuals with either neurofibromatosis type 1 (NF1) or NF2-related schwannomatosis (NF2-SWN). That work has now been published in the leading publication Nature Communications. The paper can be found here: Functional Interactions Between Neurofibromatosis Tumor Suppressors Underlie Schwann Cell Tumor Differentiation and Treatment Resistance.

Using cutting-edge techniques in genomics and biochemistry, the researchers examined samples from humans, cell lines, and animal models. The study uncovered a significant link between NF1 and NF2-SWN in the context of Schwann cell tumors. While NF1 and NF2-SWN are separate conditions caused by pathogenic variants (mutations) in different genes, this research reveals how changes in the NF2 gene can impact the behavior of Schwann cell tumors, particularly in individuals with NF1 mutations.

This has the potential to be a game-changer for patients. By understanding the connection between NF1 and NF2-SWN in the context of Schwann cell tumors, researchers may be able develop targeted therapies that can benefit patients. This could lead to more effective treatments for Schwann cell tumors and improved outcomes for individuals. It’s a significant step forward in the fight against NF.